Agilent to up Oligo API capacity with new manufacturing plant

By Gareth Macdonald

- Last updated on GMT

iStock/ktsimage
iStock/ktsimage

Related tags Nucleic acid Active ingredient

Agilent Technologies has announced plans for a nucleic acid API manufacturing plant in Colorado.

The Californian supplier said the new facility in Frederick, Weld County will supply pharmaceutical firms developing oligonucleotide-based medicines. It also predicted the investment will create up to 200 jobs.

Agilent’s nucleic acid active pharmaceutical ingredients (API) manufacturing base is in Boulder, Colorado at a facility it gained when it acquired SynPro Corp in 2006.

In 2008​, Agilent expanded the site with assets bought from Dowpharma's nucleic acid medicines business.

A year​ later it further expanded the facility, telling us shortly after that it was capable of making "several hndred kilograms of therapeutic oligonucleotides per year​."

Nucleic acid demand

Agilent’s nucleic acid API business is part of its diagnostics and genomics division.

According to the firm's most recent financial results​, the division generated $178m (€159m) in the three months to the end of April, which is an increase 5%.

Growth was driven by demand for genomics services and sequencing. However, Agilent also said that “continued market demand in the nucleic acid solutions” ​had played a part in the gains.

Related news

Nucleic acids are at the centre of Agilent’s court case against former employee and CEO of Twist Bioscience, Emily LeProust.

In a lawsuit​ filed in February, Agilent accused LeProust of stealing oligonucelutide synthesis knowhow. LeProust has rejected the allegations. The case is ongoing.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars